Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer

Autor: Dandan Li, Meiyan Liu, Lichun Sun, Xiaoqun Dong, Qingwei Meng, Guangjie Sui, Xuesong Chen, Yanmei Yang, Yanbin Zhao, Li Cai
Rok vydání: 2012
Předmět:
Adult
Vascular Endothelial Growth Factor A
Cancer Research
medicine.medical_specialty
Angiotensin receptor
Angiogenesis
Mice
Nude
Angiogenesis Inhibitors
Antineoplastic Agents
Breast Neoplasms
Losartan
Receptor
Angiotensin
Type 1
Metastasis
chemistry.chemical_compound
Mice
Internal medicine
Cell Line
Tumor
medicine
Animals
Humans
skin and connective tissue diseases
Aged
Cell Proliferation
Angiotensin II receptor type 1
biology
Neovascularization
Pathologic
business.industry
Angiotensin-converting enzyme
Middle Aged
medicine.disease
Angiotensin II
Xenograft Model Antitumor Assays
Tumor Burden
Vascular endothelial growth factor
Gene Expression Regulation
Neoplastic
Endocrinology
Oncology
chemistry
biology.protein
Cancer research
MCF-7 Cells
Female
business
Angiotensin II Type 1 Receptor Blockers
medicine.drug
Zdroj: Cancer letters. 328(2)
ISSN: 1872-7980
Popis: Angiotensin II type 1 receptor (AT1R) promotes tumor invasion, migration, metastasis and angiogenesis. We explored the potential antitumor effects of AT1R antagonists in breast cancer. We found that angiotensin II promoted cell proliferation and upregulated the expression of vascular endothelial growth factor A (VEGF-A) in MCF-7 cells. Losartan downregulated the expression of VEGF-A in MCF-7 cells treated with angiotensin II. Candesartan downregulated the expression of VEGF-A in mice bearing MCF-7 xenografts and inhibited tumor growth and angiogenesis. AT1R and VEGF-A expression correlated with increased microvascular density in 102 breast cancer patients. Our data suggest that AT1R antagonists might be useful to suppress breast cancer by inhibiting the angiotensin II.
Databáze: OpenAIRE
Externí odkaz: